132 related articles for article (PubMed ID: 11603427)
1. Predicting the sites of metastases from lung cancer using molecular biologic markers.
D'Amico TA; Aloia TA; Moore MB; Conlon DH; Herndon JE; Kinch MS; Harpole DH
Ann Thorac Surg; 2001 Oct; 72(4):1144-8. PubMed ID: 11603427
[TBL] [Abstract][Full Text] [Related]
2. The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer.
Sun D; Li X; Ma M; Liu J; Xu Y; Ye L; Hou H; Wang C; Li X; Jiang Y
Jpn J Clin Oncol; 2015 May; 45(5):464-73. PubMed ID: 25646356
[TBL] [Abstract][Full Text] [Related]
3. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain.
Grinberg-Rashi H; Ofek E; Perelman M; Skarda J; Yaron P; Hajdúch M; Jacob-Hirsch J; Amariglio N; Krupsky M; Simansky DA; Ram Z; Pfeffer R; Galernter I; Steinberg DM; Ben-Dov I; Rechavi G; Izraeli S
Clin Cancer Res; 2009 Mar; 15(5):1755-61. PubMed ID: 19190132
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
5. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
D'Amico TA; Massey M; Herndon JE; Moore MB; Harpole DH
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):736-43. PubMed ID: 10096969
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
10. PPARGC1A is upregulated and facilitates lung cancer metastasis.
Li JD; Feng QC; Qi Y; Cui G; Zhao S
Exp Cell Res; 2017 Oct; 359(2):356-360. PubMed ID: 28803067
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for brain metastases in patients with non-small-cell lung cancer.
An N; Jing W; Wang H; Li J; Liu Y; Yu J; Zhu H
Cancer Med; 2018 Dec; 7(12):6357-6364. PubMed ID: 30411543
[TBL] [Abstract][Full Text] [Related]
12. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.
Improta G; Zupa A; Fillmore H; Deng J; Aieta M; Musto P; Liotta LA; Broaddus W; Petricoin EF; Wulfkuhle JD
J Proteome Res; 2011 Jul; 10(7):3089-97. PubMed ID: 21574647
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
Saad AG; Yeap BY; Thunnissen FB; Pinkus GS; Pinkus JL; Loda M; Sugarbaker DJ; Johnson BE; Chirieac LR
Cancer; 2008 Oct; 113(8):2129-38. PubMed ID: 18720359
[TBL] [Abstract][Full Text] [Related]
14. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
15. Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers.
Lee YC; Chang YL; Luh SP; Lee JM; Chen JS
Ann Thorac Surg; 1999 Aug; 68(2):343-7; discussion 348. PubMed ID: 10475393
[TBL] [Abstract][Full Text] [Related]
16. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
17. Molecular biologic substaging of stage I lung cancer according to gender and histology.
D'Amico TA; Aloia TA; Moore MB; Herndon JE; Brooks KR; Lau CL; Harpole DH
Ann Thorac Surg; 2000 Mar; 69(3):882-6. PubMed ID: 10750777
[TBL] [Abstract][Full Text] [Related]
18. p53, BCL-2 and BAX in non-small cell lung cancer brain metastases: a comparison of real-time RT-PCR, ELISA and immunohistochemical techniques.
Stark AM; Hugo HH; Tscheslog H; Mehdorn HM
Neurol Res; 2007 Jul; 29(5):435-40. PubMed ID: 17535549
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
Kinch MS; Moore MB; Harpole DH
Clin Cancer Res; 2003 Feb; 9(2):613-8. PubMed ID: 12576426
[TBL] [Abstract][Full Text] [Related]
20. [Multimodal Treatment of Non-Small Cell Lung Cancer with Cerebral Metastases].
Kudelin N; Bölükbas S; Schirren J
Zentralbl Chir; 2015 Jun; 140(3):328-33. PubMed ID: 26114639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
